

Prostate Specific Antigen - Pipeline Review, H1 2020

<https://marketpublishers.com/r/PDB4E452BDB7EN.html>

Date: February 2020

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: PDB4E452BDB7EN

Abstracts

Prostate Specific Antigen - Pipeline Review, H1 2020

SUMMARY

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Hormone-Sensitive Prostate Cancer.

The latest report Prostate Specific Antigen - Pipeline Review, H1 2020, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics

Development

Advaxis Inc

Bavarian Nordic A/S

Etubics Corp

Hookipa Pharma Inc

Inovio Pharmaceuticals Inc

NantKwest Inc

Ohana Vaccine LLC

OncBioMune Pharmaceuticals Inc

OncoQuest Inc

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles

ADX-PSA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-071 + ETBX-061 + ETBX-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pro-V vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proscavax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilimogene galvacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate

Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones

Featured News & Press Releases

Feb 13, 2020: Advaxis announces updated survival data in phase 1/2 ADXS-PSA trial at the ASCO Genitourinary Cancers Symposium

Jan 30, 2020: Data on Advaxis' clinical program ADXS-PSA to be presented at upcoming medical meetings

Oct 07, 2019: Advaxis announces updated prolonged survival data in phase 1/2 ADXS-PSA trial

May 14, 2019: Advaxis announces poster presentation on ADXS-PSA at the Frontiers in Cancer Immunotherapy Conference

May 07, 2019: Advaxis presents on its prostate cancer drug candidate ADXS-PSA at upcoming industry conferences

Apr 01, 2019: ADXS-PSA in combination with Keytruda prolonged survival in metastatic castration-resistant prostate cancer

Mar 19, 2019: Phase 2 trial of OncBioMune's immunotherapy cancer vaccine

Proscavax for prostate cancer patients in active surveillance now open for enrollment

Mar 11, 2019: Advaxis announces presentation of ADXS-PSA data at upcoming American Association for Cancer Research Annual Meeting

Jan 25, 2019: Data highlighting potential benefits of Im platform presented at 2019 Keystone Symposia Conference on cancer vaccines

Dec 07, 2018: Site visit planned for December 19, 2018 to initiate phase 2 Trial of Proscavax for early-stage prostate cancer

Nov 08, 2018: OncBioMune phase 2 clinical trial to begin enrollment; company announces other development and corporate milestones

Nov 02, 2018: Advaxis provides update on its Prostate Cancer drug candidate ADXS-PSA

Oct 31, 2018: OncBioMune CEO Dr. Jonathan head speaking at 2018 global summit on genitourinary malignancies

Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

Oct 16, 2018: OncBioMune Signs Work Order for Phase 2 Clinical Trial of Proscavax for Late Stage Prostate Cancer

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Advaxis Inc, H1 2020
Pipeline by Bavarian Nordic A/S, H1 2020
Pipeline by Etubics Corp, H1 2020
Pipeline by Hookipa Pharma Inc, H1 2020
Pipeline by Inovio Pharmaceuticals Inc, H1 2020
Pipeline by NantKwest Inc, H1 2020
Pipeline by Ohana Vaccine LLC, H1 2020
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2020
Pipeline by OncoQuest Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Advaxis Inc

Bavarian Nordic A/S

Etubics Corp

Hookipa Pharma Inc

Inovio Pharmaceuticals Inc

NantKwest Inc

Ohana Vaccine LLC

OncBioMune Pharmaceuticals Inc

OncoQuest Inc

I would like to order

Product name: Prostate Specific Antigen - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/PDB4E452BDB7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PDB4E452BDB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970